Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9BUQ8
UPID:
DDX23_HUMAN
Alternative names:
100 kDa U5 snRNP-specific protein; DEAD box protein 23; PRP28 homolog; U5-100kD
Alternative UPACC:
Q9BUQ8; B2R600; B4DH15; O43188
Background:
Probable ATP-dependent RNA helicase DDX23, also known as 100 kDa U5 snRNP-specific protein, DEAD box protein 23, PRP28 homolog, and U5-100kD, plays a crucial role in pre-mRNA splicing. Its phosphorylated form, activated by SRPK2, is essential for the formation of the spliceosomal B complex. Beyond spliceosome assembly, DDX23 is vital for preventing the formation of incorrect R-loops during transcription, which are detrimental DNA:RNA hybrids.
Therapeutic significance:
Understanding the role of Probable ATP-dependent RNA helicase DDX23 could open doors to potential therapeutic strategies.